Contribute Try STAT+ Today

Clinical trials are an essential component of bringing new, innovative medicines to market and answering complex questions about whether experimental treatments are safe and effective enough to prescribe to patients.

But the current model for clinical trials has some fundamental flaws that increasingly affect both patients and the entire health care system.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The first concern about this type of app, is the countless number of devices that already have had problems with even the most simple data that are either missing or mis-used by the app developer, and is also a subscriber to a Pharma company who has received the data, and find the individuals who have received treatment for their respective health issues, and are then the same individuals who are denied receiving any treatments because of a “pre-existing condition.”

    When we elect to have our personal health care issues on the internet, we are just giving these Pharma companies the opportunity to turn away the most significant individuals who are in dire need of a treatment modality that could actually provide them with a more quality of life experience. Then they are placing a target on their own selves to be omitted from the treatment protocol because as the author claims they are not able to provide the money for such a program; thus the very population that is the reason stated that this is the most significant reason for why the companies want to provide this opportunity, and one has to wonder why? The author states that they are in need of more funding to provide the best clinical trials to the same people who are already probably not considered as a clinical trial responder, because they are not going to provide the company with a profit margin of success. I am also more than suspicious of what those same individuals are then chosen for the non treatment group that would provide the company with a professional clinical trial experience, that begs the question, of which group they are chosen to be a part of the trial group.

    Finally, we are allowing our personal health issues to appear on the internet, and we are all aware of how “safe,” the information is when on the internet.

    We have so many different ways to get our transportation issues resolved before we go through this rather unknown modality for our health care experience. I don’t think so; and how is the HIPPAA law compromised with this type of clinical trial? I would personally never agree to be a patient in this manner.

    • Hi David – Absolutely – telemedicine will be a critical component of a decentralized model. Shortly, I will be sharing some interesting work we just completed at Novartis working with Medgate–one of the largest telemedicine providers in the EU. It would be great to connect on LinkedIn

Comments are closed.